HUMALOG KWIKPEN (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 2015.
Drug data last refreshed 12h ago · AI intelligence enriched 2d ago
HUMALOG KWIKPEN is a rapid-acting insulin analog (insulin lispro) administered via subcutaneous injection using a prefilled pen device. It is indicated for blood glucose management in patients with diabetes mellitus who require insulin therapy. The drug works by mimicking endogenous insulin to promote glucose uptake and utilization in peripheral tissues.
Peak lifecycle status indicates established market presence with stable revenue generation; commercial teams are focused on market defense and operational efficiency rather than launch activities.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
Worked on HUMALOG KWIKPEN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moEli Lilly and Company is hiring 2 roles related to this product
Working on HUMALOG KWIKPEN positions you in a mature, high-volume commercial franchise with stable revenue but limited growth potential; career advancement depends on market defense, payer negotiations, and operational optimization rather than launch activities. Roles emphasize field execution, account management, and managed care strategy in an increasingly commoditized insulin market.